Johnson & Johnson Announces Two-year Data From Its Phase 3 ICONIC-TOTAL Study Of ICOTYDE On High-Impact Plaque Psoriasis Sites; 60% Of Patients With Scalp Psoriasis And 89% With Genital Psoriasis Achieved Site-Specific Complete Skin Clearance At Week 112

Johnson & Johnson presented two-year data from its Phase 3 ICONIC-TOTAL study of ICOTYDE for treating high-impact plaque psoriasis at the EADV Congress 2026. The study showed that 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved complete skin clearance at Week 112. Additionally, the overall rate of clear or almost clear skin increased from 57% at Week 16 to 70% at Week 112. The safety profile of ICOTYDE remained consistent with previous findings, with no new safety signals identified.